Hong Kong-listed Zylox-Tonbridge has agreed to acquire German medtech Optimed, in a deal aimed at speeding up its international expansion.
Under the agreement, Zylox-Tonbridge will acquire Optimed’s equity interest in multiple steps, with an option to purchase the entire shareholding from the current owners.
Zylox-Tonbridge specialises in neurovascular and peripheral vascular interventional products, medical devices used in minimally invasive procedures involving blood vessels in the brain and body.
Optimed focuses on the research, development, production and distribution of devices for minimally invasive therapies globally.
Optimed has been in operation for nearly 30 years, establishing a sales and service network that extends to more than 70 countries.
The company offers a range of products in the peripheral venous stenting segment, including devices designed for the iliofemoral veins, vena cava and iliac bifurcation.
Clinical evidence for its venous stents includes data from trials such as sinus-Venous and STEVECO, with STEVECO described as the first prospective, multicentre, randomised study in chronic deep venous obstruction.
Results from these trials indicated improvements in quality of life and clinical severity compared with conservative treatment.
The acquisition is designed to accelerate global expansion by creating a unified platform spanning research and development, manufacturing and commercialisation.
By integrating both companies’ sales networks and leveraging Optimed’s established relationships with European clinical experts, Zylox-Tonbridge aims to bring products to market more efficiently and extend its international reach.
The partnership is expected to deliver operational synergies through an expanded manufacturing base in Germany. This will support a reliable supply of medical solutions for European and global markets.
After completion of the transaction, Zylox-Tonbridge will merge its sales, marketing and customer service teams with those of Optimed to establish a unified global commercial organisation.
Rüdiger Hausherr will continue as chief executive of Optimed and report to Dr Jonathon Zhong Zhao, chairman and chief executive of Zylox-Tonbridge.
Zhao said: “This acquisition marks an important milestone in Zylox-Tonbridge’s global strategy, enabling the company to leverage a broader European-based platform to accelerate its global expansion.”
“We are very pleased to welcome Optimed to the Zylox-Tonbridge Group and look forward to combining our complementary product portfolios and manufacturing platforms to bring high-quality, innovative and affordable solutions to more patients and physicians worldwide, while driving the company’s next phase of growth.”
